NasdaqCM - Nasdaq Real Time Price USD

Immatics N.V. (IMTX)

5.98
-0.03
(-0.50%)
As of 3:47:04 PM EDT. Market Open.
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
144,148
155,835
53,997
172,831
34,763
Operating Expense
204,668
194,450
155,722
142,877
121,057
Operating Income
-60,520
-38,615
-101,725
29,954
-86,294
Net Non Operating Interest Income Expense
23,229
24,115
13,014
1,438
-433
Other Income Expense
19,510
35,846
-8,283
10,644
-6,608
Pretax Income
-17,781
21,346
-96,994
42,036
-93,335
Tax Provision
4,616
6,128
-2,345
14,333
0
Net Income Common Stockholders
-22,397
15,218
-94,649
27,703
-93,335
Diluted NI Available to Com Stockholders
-22,397
15,218
-94,649
27,703
-93,335
Basic EPS
-0.17
0.14
-1.18
0.56
-1.48
Diluted EPS
-0.17
0.14
-1.18
0.55
-1.48
Basic Average Shares
111,447.42
105,744.93
80,546.68
66,989.29
62,912.92
Diluted Average Shares
111,447.42
106,795.10
80,546.68
68,207.27
62,912.92
Total Operating Income as Reported
-60,520
-38,615
-101,725
29,954
-86,294
Total Expenses
204,668
194,450
155,722
142,877
121,057
Net Income from Continuing & Discontinued Operation
-22,397
15,218
-94,649
27,703
-93,335
Normalized Income
-38,980.50
-10,337.35
-86,566.26
20,688.28
-86,727
Interest Income
24,170
25,001
13,845
2,476
133
Interest Expense
941
886
831
1,038
566
Net Interest Income
23,229
24,115
13,014
1,438
-433
EBIT
-16,840
22,232
-96,163
43,074
-92,769
EBITDA
-4,489
34,457
-88,929
50,041
-87,509
Reconciled Depreciation
12,351
12,225
7,234
6,967
5,260
Net Income from Continuing Operation Net Minority Interest
-22,397
15,218
-94,649
27,703
-93,335
Total Unusual Items Excluding Goodwill
19,510
35,846
-8,283
10,644
-6,608
Total Unusual Items
19,510
35,846
-8,283
10,644
-6,608
Normalized EBITDA
-23,999
-1,389
-80,646
39,397
-80,901
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
2,926.50
10,290.65
-200.26
3,629.28
0
12/31/2021 - 12/12/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

IDYA IDEAYA Biosciences, Inc.
21.67
+2.12%
 
LXEO Lexeo Therapeutics, Inc.
2.8200
+3.68%
 
IMCR Immunocore Holdings plc
38.78
+0.34%
 
MLTX MoonLake Immunotherapeutics
48.77
+18.49%
 
BCAX Bicara Therapeutics Inc.
11.07
+11.82%
 
TRVI Trevi Therapeutics, Inc.
6.01
-4.91%
 
OLMA Olema Pharmaceuticals, Inc.
4.0950
-6.40%
 
ACTU Actuate Therapeutics, Inc. Common stock
10.00
-5.57%
 
PTGX Protagonist Therapeutics, Inc.
51.34
+2.37%
 
NRIX Nurix Therapeutics, Inc.
12.12
-0.16%